JP2024042072A5 - - Google Patents

Download PDF

Info

Publication number
JP2024042072A5
JP2024042072A5 JP2024014900A JP2024014900A JP2024042072A5 JP 2024042072 A5 JP2024042072 A5 JP 2024042072A5 JP 2024014900 A JP2024014900 A JP 2024014900A JP 2024014900 A JP2024014900 A JP 2024014900A JP 2024042072 A5 JP2024042072 A5 JP 2024042072A5
Authority
JP
Japan
Prior art keywords
seq
sequence
abp
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024014900A
Other languages
English (en)
Japanese (ja)
Other versions
JP7745669B2 (ja
JP2024042072A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/068820 external-priority patent/WO2020140084A1/en
Application filed filed Critical
Publication of JP2024042072A publication Critical patent/JP2024042072A/ja
Publication of JP2024042072A5 publication Critical patent/JP2024042072A5/ja
Priority to JP2025100129A priority Critical patent/JP2025128343A/ja
Application granted granted Critical
Publication of JP7745669B2 publication Critical patent/JP7745669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024014900A 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法 Active JP7745669B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025100129A JP2025128343A (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof
JP2021537082A JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021537082A Division JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025100129A Division JP2025128343A (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2024042072A JP2024042072A (ja) 2024-03-27
JP2024042072A5 true JP2024042072A5 (enExample) 2024-10-18
JP7745669B2 JP7745669B2 (ja) 2025-09-29

Family

ID=71126610

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法
JP2025100129A Pending JP2025128343A (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025100129A Pending JP2025128343A (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Country Status (12)

Country Link
US (1) US12421311B2 (enExample)
EP (1) EP3902821A4 (enExample)
JP (3) JP7558949B2 (enExample)
KR (1) KR20210121045A (enExample)
CN (2) CN114008071B (enExample)
AU (2) AU2019413366B2 (enExample)
BR (1) BR112021012588A2 (enExample)
CA (1) CA3124961C (enExample)
IL (2) IL316757A (enExample)
MX (1) MX2021007848A (enExample)
SG (1) SG11202106764YA (enExample)
WO (1) WO2020140084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250157457A (ko) * 2015-10-23 2025-11-04 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
AU2021299338A1 (en) * 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
EP4362981A1 (en) * 2021-07-02 2024-05-08 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
KR20240114766A (ko) * 2021-12-10 2024-07-24 머크 샤프 앤드 돔 엘엘씨 인간 메소텔린 결합제
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP6449338B2 (ja) * 2014-06-06 2019-01-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘導腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
CA2976446A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
SI3303394T1 (sl) * 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
US10618960B2 (en) 2015-12-15 2020-04-14 Oncoimmune, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018157147A1 (en) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
JP7173993B2 (ja) * 2017-05-19 2022-11-17 ウーシー バイオロジクス(シャンハイ)カンパニー リミテッド 細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対する新規モノクローナル抗体
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
IL316757A (en) 2018-12-27 2025-01-01 Gigagen Inc Anti-CTLA-4 binding proteins and methods of using them
TWI850316B (zh) 2019-01-21 2024-08-01 法商賽諾菲公司 用於晚期實性瘤癌症之治療性rna及抗pd1抗體
AU2021299338A1 (en) 2020-07-02 2023-02-23 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024042072A5 (enExample)
JP2025128343A5 (enExample)
Wang et al. The state of the art of bispecific antibodies for treating human malignancies
JP2020504076A5 (enExample)
JP2023123726A5 (enExample)
JP2019536430A5 (enExample)
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
Xiong et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody
JP2009541492A5 (enExample)
JP2013527761A5 (enExample)
JP2019513777A5 (enExample)
JP2020515247A5 (enExample)
JP2011207882A5 (enExample)
WO2013140787A1 (ja) 特発性炎症性筋疾患の予防又は治療剤
JP2023182689A5 (enExample)
JPWO2020172605A5 (enExample)
JP2024020436A5 (enExample)
JPWO2006046661A1 (ja) インターロイキン−6阻害剤
JPWO2022044573A5 (enExample)
JPWO2023288241A5 (enExample)
JPWO2023034922A5 (enExample)
JPWO2022067262A5 (enExample)
JP7539609B2 (ja) 抗-cd300c単クローン抗体を含むがん予防または治療用組成物
JPWO2022114163A5 (enExample)
JPWO2022256559A5 (enExample)